Insurance Navigation & Financial Help

We do not want concerns about cost or insurance coverage to come between you and your medication. Our Nurse Advocates are here to offer information about financial assistance options that may be available to you, as well as explain your insurance coverage, and help determine if OGSIVEO^® (nirogacestat) is covered.

If you have commercial health insurance, you may pay as little as a $0 copay with the Commercial Copay Program. There are no income requirements to participate in the program.*

Enroll in a Copay Program

Patient Assistance Program (PAP)

If you are uninsured, lack coverage for OGSIVEO, or are experiencing financial hardship, the Patient Assistance Program may help you obtain OGSIVEO at no cost.*

Terms and conditions apply. Copay program is subject to an annual benefit maximum. PAP eligibility criteria and annual household income limits apply. Full terms and conditions provided during the enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Independent Patient Assistance Foundations

Financial assistance may be available through independent foundations that are not controlled by or otherwise affiliated with SpringWorks Therapeutics. These foundations may be able to assist with, for example, copays, premiums, patient education, and social services.

Explore additional foundations that may be able to help with financial assistance  

Find foundations

This link is created by Real Endpoints. Real Endpoints is independent of SpringWorks Therapeutics. SpringWorks Therapeutics is providing a link to these foundations to help patients find more information about potential assistance, but inclusion on this list does not represent an endorsement or a recommendation from SpringWorks for any group or organization. The organizations listed are independent of SpringWorks and SpringWorks does not influence or control the operations of independent patient assistance foundations. SpringWorks cannot guarantee assistance will be provided. Details and eligibility requirements can be found directly on the individual foundation websites.

Temporary Free Medication Programs for Eligible Patients

These programs may help you if your insurance coverage is delayed, or you experience a gap in your insurance coverage.

QUICK START PROGRAM

Available to eligible commercially insured patients and may help you start on OGSIVEO at no cost for a limited period of time if your insurance company is delayed in making a coverage decision.^†

Learn more

Eligible patients experiencing a qualified delay in their insurance coverage may receive an initial supply of OGSIVEO, and up to 1 refill, subject to program terms.

If you are waiting to see if your insurance will cover OGSIVEO, talk to your doctor, or call one of our Nurse Advocates to learn more about the Quick Start Program.

BRIDGE PROGRAM

Available to eligible patients and may provide you with OGSIVEO at no cost for a limited period of time if you experience an interruption or gap in coverage.^†

Learn more

Eligible patients experiencing a qualified lapse in their insurance coverage may receive an initial supply of OGSIVEO, and up to 2 refills, subject to program terms.

If you are currently on OGSIVEO and your insurance has changed, talk to your doctor, or call one of our Nurse Advocates to learn more about the Bridge Program.

^†	Terms and conditions apply. Full terms and conditions provided during enrollment process and are available upon request by contacting SpringWorks CareConnections at 844-CARES-55 (844-227-3755).

Enrollment in SpringWorks 
CareConnections is simple

Enroll

Have Questions?

Call SpringWorks
CareConnections today

844-CARES-55
(844-227-3755)

Monday-Friday
8 AM-10 PM ET

Privacy Policy

Terms of Use

Cookie Policy

Sitemap

OGSIVEO is a registered trademark of SpringWorks Therapeutics, Inc. GOMEKLI and SpringWorks CareConnections are trademarks of SpringWorks Therapeutics, Inc. All other trademarks are the property of their respective owners.

This site is intended for U.S. audiences only.

Privacy Policy

Terms of Use

Cookie Policy

Sitemap